Immuto Scientific is on a mission to demystify and democratize protein structure, function, and dynamics - revolutionizing drug discovery and therapeutic development. Via our proprietary platform, we generate detailed, native-state structures at amino acid-level resolution for any protein or peptide, alone or in a complex, in just a few weeks.
Protein structural analysis is an essential step in the drug discovery process, and compared to all other methods used today, our suite of proprietary technologies enables developers to investigate interactions of therapeutics and their targets with an unprecedented degree of accuracy and speed.
That means significantly reducing uncertainty — and the costs related to it.
Unlike other methods, our groundbreaking suite of technologies for the first time makes it possible to map epitopes and paratopes quickly, reliably through a native, in-solution analysis.
We partner with pharmaceutical companies in drug discovery to streamline their lead optimization, helping to reduce cycle times, increase lead candidates, and maximize the probability of drug success leading up to clinical trials.
Get results in 2–3 weeks to perform rapid lead optimization iteration
Can be performed on many lead candidates simultaneously
Native structure and protein conditions for biologically-relevant results
Better epitope findings earlier make for stronger claims
Can be used to analyze challenging protein targets
Our core proprietary technology, PLIMB (Plasma Induced Modification of Biomolecules) is setting a new standard for epitope mapping and structural analysis.
PLIMB provides high-resolution data on antibody binding while eliminating other costly inefficiencies, so developers can zero-in on multiple high-probability leads at the same time.
Our core proprietary technology, PLIMB (Plasma Induced Modification of Biomolecules) is setting a new standard for epitope mapping and structural analysis.
PLIMB provides high-resolution data on antibody binding while eliminating other costly inefficiencies, so developers can zero-in on multiple high-probability leads at the same time.
Our findings have been published in some of the most prestigious peer-reviewed journals. Your therapeutics save lives. We save you time and resources.
Plasma-Generated OH Radical Production for Analyzing 3D Structure
Effect of Frequency and Applied Voltage of An Atmospheric-Pressure
October 9, 2021
Immuto Scientific raises $2.3 million in seed funding
Measuring the Conformational Effects of RORG Residues
Protein structural analysis is an essential step in the drug discovery process, and compared to all other methods used today, our suite of proprietary technologies enables developers to investigate interactions of therapeutics and their targets with an unprecedented degree of accuracy and speed.
That means significantly reducing uncertainty —
and the costs related to it.
Unlike other methods, our groundbreaking suite of technologies for the first time makes it possible to map epitopes and paratopes quickly, reliably through a native, in-solution analysis.
We partner with pharmaceutical companies in drug discovery to streamline their lead optimization, helping to reduce cycle times, increase lead candidates, and maximize the probability of drug success leading up to clinical trials.
No lengthy protein crystallization required
Performed in biologically-relevant buffer
Requires minimal sample sizes (>5ug per sample)
High throughput for multiple, synchronous targeting
Analyzes proteins incompatible with other techniques
Prevents denaturization through sub-microsecond timescale
Our core proprietary technology, PLIMB (Plasma Induced Modification of Biomolecules) is setting a new standard for epitope mapping and structural analysis.
PLIMB provides high-resolution data on antibody binding while eliminating other costly inefficiencies, so developers can zero-in on multiple high-probability leads at the same time.
Our team is made up of leading scientists and researchers boasting a collective 20+ years of experience in protein biochemistry, mass spectrometry, and drug discovery and development. Our state-of-the-art technologies and expertise are changing drug discovery as we know it.
Our findings have been published in some of the most prestigious peer-reviewed journals. Your therapeutics save lives. We save you time and resources.
We’ve attracted the attention of industry leaders, investors, and clients, including the top pharmaceutical companies and biotechnology firms in the US, and these esteemed institutional partners.
University of Wisconsin Madison
Wisconsin Alumni Research Foundation
National Science Foundation
Wisconsin Investment Partners
Milwaukee Venture Partners
National Institute of Health
